Sleep Assessment in Long COVID Clinics
A Necessary Tool for Effective Management
Citation Manager Formats
Make Comment
See Comments

Abstract
As we adapt to SARS-CoV-2, it has become apparent that the acute illness is not the only threat from this virus. Long COVID has emerged as a potentially disabling condition with multiple varied symptoms. We propose that querying patients about their sleep may allow for the assessment of a sleep-related disorder that is amenable to treatment. In addition, hypersomnolence is a prominent feature and may mimic other organic hypersomnias; therefore, inquiring about COVID-19 infection in sleepy patients is suggested.
Recent studies suggest that a significant proportion of individuals who had a COVID-19 infection developed 1 or more sequelae including fatigue, brain fog, depression, anxiety, breathlessness, and sleep disturbance.1 Symptoms may range from mild to debilitating. A collection of these symptoms is referred to as “long COVID” or postacute sequelae of SARS-CoV-2 infection.
Many health care facilities across the world are seeing an increasing number of patients with long COVID. Numerous post-COVID clinics have been established, usually headed by neurology, pulmonary, or physical medicine and rehabilitation clinicians. On behalf of the COVID-19 Task Force of the American Academy of Sleep Medicine, we applaud their efforts and suggest collaboration with sleep medicine clinicians. Thus far, in our collective experience, sleep disturbances and fatigue, often significant enough to continue to impair daytime functioning for weeks or months after initial infection, seem to be a prominent feature in patients with long COVID; yet a formal sleep assessment does not seem to be a routine part of the post-COVID clinic protocols.2 We submit that because sleep disturbances are such a common feature of long COVID, clinicians should routinely ask post-COVID patients about their sleep and screen for sleep complaints. A sleep medicine evaluation may uncover a disorder amenable to treatment that may hasten symptom improvement or resolution. Similarly, sleep medicine clinicians may wish to query patients routinely regarding whether they have recovered from COVID-19 if sleep complaints continue to persist beyond resolution of acute illness or if new symptoms have arisen or evolved since the time of initial infection.
Recent studies have shown that patients with obesity and obstructive sleep apnea (OSA) have worse clinical outcomes when hospitalized with COVID-19.3,-,5 It is quite plausible that a proportion of patients with long COVID have undiagnosed OSA. Patients with lung damage from acute COVID–related pneumonia may have ongoing pulmonary insufficiency as well and an abnormal alveolar-arterial O2 gradient, which can exacerbate the risk for nocturnal desaturation or sleep apnea. In these cases, OSA should be considered even if traditional risk factors are absent when evaluating a patient with new fatigue. Although OSA has not been classified by the Centers for Disease Control and Prevention as an independent risk factor for the acquisition of COVID-19, there are data demonstrating worse COVID outcomes in patients with nocturnal hypoxia and sleep apnea.6 Identifying and treating OSA early may be fruitful, and creating an inpatient sleep program and/or screening for OSA during hospitalization should be considered.
In addition to OSA, sleep fragmentation may present as insomnia in the form of both sleep-onset and sleep-maintenance difficulties and/or nonrestorative sleep. Persistent sleep disturbance may lead to chronic insomnia. Hypersomnia disorders should be considered if a significant degree of daytime fatigue or sleepiness is present. In these cases, further testing with in-laboratory polysomnography, actigraphy, sleep logs, or multiple sleep latency testing may be necessary. Circadian rhythm misalignment also may contribute to symptoms of long COVID.
Moving forward, we propose including sleep medicine clinicians as part of long COVID multidisciplinary clinics. We recognize that not all facilities have a sleep clinician on site and propose that standard screening tools such as the STOP-Bang or PROMIS assessment tools be deployed. In patients who report falling asleep during the daytime, the Epworth Sleepiness Scale score can be helpful, with a score >10 indicating pathologic sleepiness.7 Those who screen positive on any of these scales may be referred for further evaluation to a sleep clinician.
We also encourage sleep medicine clinicians to ask about a history of COVID-19 infection and about long COVID symptoms. We applaud the efforts of the NIH to identify and fund high-priority research areas to study sleep disorders and disturbance in long COVID—the role of sleep and sleep and circadian rhythm disorders; the prevalence of such disorders in long COVID; and whether treatment of sleep disorders affects long-term outcomes.8 These concerted efforts in the clinical and scientific domains may help our patients, yield useful information about the interaction between sleep and COVID-related outcomes, and boost our preparedness for future pandemics.
Acknowledgment
The authors thank the members of the AASM COVID-19 Task Force for their input and comments: Elena Beam, MD (Department of Internal Medicine, Division of Infectious Disease, Mayo Clinic, Rochester, MN); Michael Berneking, MD (Concentra, Inc., Grand Rapids, MI); Lawrence J. Epstein, MD (Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Division of Sleep Medicine, Harvard Medical School, Boston, MA); Brittany J. Meyer, MD (ProHealth Care Sleep Center, Delafield, WI, Sweet Dreams Sleep Services, Gering, NE); Kannan Ramar, MD (Division of Pulmonary and Critical Care Medicine, Center for Sleep Medicine, Mayo Clinic, Rochester, MN); Jennifer Y. So, MD (Division of Pulmonary, Critical Care and Sleep Medicine, University of Maryland School of Medicine, Baltimore, MD); Shannon S. Sullivan, MD (Division of Pulmonary, Asthma, and Sleep Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA); Lisa F. Wolfe, MD (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, Thomas Heffron (AASM).
Study Funding
The authors report no targeted funding.
Disclosure
The authors report no relevant disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Appendix Authors

Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Submitted and externally peer reviewed. The handling editor was Associate Editor Belinda A. Savage-Edwards, MD, FAAN.
COVID-19 Resources: NPub.org/COVID19
- Received March 28, 2022.
- Accepted August 11, 2022.
- © 2023 American Academy of Neurology
References
- 1.↵Centers for Disease Control and Prevention. Post-COVID conditions. 2021. Accessed December 28, 2021.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
- 2.↵
- Walter K
- 3.↵
- Peker Y,
- Celik Y,
- Arbatli S, et al.
- 4.↵
- Maas MB,
- Kim M,
- Malkani RG,
- Abbott SM,
- Zee PC
- 5.↵
- 6.↵
- Pena Orbea C,
- Wang L,
- Shah V, et al.
- 7.↵
- Johns MW
- 8.↵National Institutes of Health. National Heart, Lung, and Blood Institute. Newly emerging research opportunity: COVID-19 pandemic. Updated December 13, 2021. Accessed December 28, 2021. nhlbi.nih.gov/sleep-research-plan/covid-19.
The Nerve!: Rapid online correspondence
- RE: It is necessary to treat OSAS in the early stage of COVID-19
- Calixto Machado, Full Professor and Researcher in Neurology, Institute of Neurology and Neurosurgery, Department of Clinical Neurophysiology, Havana, Cuba
Submitted February 09, 2023
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.